Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2013)
20 slides from Vita Life Sciences's shareholder meeting presentation, May 23, 2013
Slide 1: Welcome to the 2013 Annual General Meeting
Welcome to the 2013 Vita Life Sciences Limited Annual General Meeting herbsofgald Viral ife — VitaScienc inal for life Dedicated fo your health Enriching Lives .Since 1947 Vi 23 May 2013
Slide 2: This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis
Slide 3: Chairman's Welcome Address
Chairman’s Welcome Address
Slide 4: Agenda: Chairman's Welcome Address
1 Chairman 1. Chairman’s s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 5: Managing Director's Review
Managing Directors Review
Slide 6: Pharmaceutical and healthcare Over-The-Counter business
Pharmaceutical and healthcare Over-The-Counter business Wide range of supplements, vitamins, minerals, meal replacement, sports nutrition and herbal care Branded under: “Herbs of Gold” throughout Australia and China “VitaHealth” and “VitaLife” throughout Asia 5
Slide 7: Established Business Units
Established Business Units: Australia, Malaysia and Singapore New Business Units: Multi-Level- Marketing (MLM) in Malaysia, China, Thailand and Vietnam Indonesia currently being established. Focus currently on product registration and preparations ti f commencementt for of operations in 2013
Slide 8: Year ended 31 December 2012 results
Year ended 31 December 2012 2011 Change $m $m % Revenue 30 191 30.191 24 267 24.267 24 4% 24.4% EBIT 2.865 1.489 92.4% Profit Before Tax 2.841 1.403 102.5% Profit After Tax 2.316 1.213 90.9% EPS (cents) 4.14 2.12 95.3% Dividend (cents) 1 00 1.00 0 50 0.50 100 0% 100.0% 7
Slide 9: Revenue
Compound Annual Growth Rate (CAGR) of 14.3% over last 4 years Revenue‐$'m Sales growth (in local currency): Established Business Units 30.191 Australia 25.1% (2011: 14.1%) Malaysia* 24.0% (2011: 24.7%) * excluding MLM 24.267 Singapore 15.5% (2011: -2.9%) 20.988 New Business Units Thailan
Slide 10: Malaysia and Singapore revenue
Malaysia** Malaysian Ringggit (million) 26.292 21.195 CAGR over 4 years of 15.8% 14.639 17.001 Current year increase 24.0% (2011: 24.7%) * MLM not included as classified as a New Business Unit 1 2 3 4 5.702 n) Singapore dollar (million 5.084 4.936 4.154 Singapore CAGR over 4 years of 8.2% Cu
Slide 11: Australia
Australia A t li remains i th the llargestt contributor to Group revenue with 45% (2011 :45%) “Other” includes China, Indonesia, Thailand and Vietnam Other increased to 7% of Group revenue (2011: 3%). Bulk of this increase is due to Thailand being consolidated for the first time in 2012 10
Slide 12: Balance Sheet
Balance Sheet ($ m) 2012 2011 Group remains debt-free, with cash hbbalance l off $5 $5.0m 0 (2011 (2011: Current assets 15.58 10.93 $3.6m) Non-current Non current assets 1 23 1.23 2 42 2.42 Cash and cash equivalents make up 44.2% of net assets Total assets 16.81 13.35 Increased investment in C
Slide 13: Cash Flow
Cash Flow ($ m) 2012 2011 Receipts from customers 32.74 26.26 Payments to suppliers and employees (31.13) (25.44) Gross operating cashflow Gross operating cash flow 1 61 1.61 0 82 0.82 ratio has improved EBITDA 2.87 1.49 marginally in FY12 Ratio of gross operating cash flow to EBITDA 56.1% 55.0% N
Slide 14: Final dividend declared
0.5 cent per share final dividend declared for the year ending 31 December 2012. Total dividend for the financial yyear of 1.0 cent per p share Represents dividend payout ratio of 24% Directors aiming to increase this ratio to approximately 33% for the foreseeable future Due to prior year ta
Slide 15: Outlook and FY13 EBIT target
The CAGR for revenue of 13% pa over the last 3 years is expected to continue in FY13 and potentially increase as the New Business Units start to make larger contributions Over the same period EBIT CAGR has shown an increase of 54% reflecting the gains made in cost control and operating leverage
Slide 16: Chairman's Address
1. Chairman Chairman’s s Address 2. Managing Director’s Review 3. Ordinary Resolutions 4 Question 4. Q ti & Answer A Ti Time
Slide 17: Remuneration Report and resolutions
1. Remuneration Report 2. Re-election of Director – Vanda Gould 3 Re-election 3. Re election of Director – Jonathan Tooth 4. Share buy-back y 5. Long Term Incentive Plan – Amendment to a li it d recourse loan limited l to t Managing M i Di Director t 6 Long Term Incentive Plan – Amendment to a 6. li
Slide 18: Proxy voting results on resolutions
PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN TOTALS DISCRETION 1) Adoption of the Remuneration 16,188,342 31,062 774,064 11,034 17,004,502 Report 2)) Election of Director ((Mr V Gould)) 16,990,881 , , 2,587 , - 11,034 , 17,004,502 , , 3) Election of Director (Mr J Tooth) 16,721,914 11,293 260,261 1
Slide 19: Chairman's Address
1. Chairman Chairman’s s Address 2. Managing Director’s Review 3. Ordinary Resolutions 4 Question 4. Q ti & Answer A Ti Time
Slide 20: Thank You
Th k You Thank Y 23 May 2013